NovoCure GmbH

Industry · 9 registered clinical trials — 2 currently recruiting.

Status	Trial	Phase	Started
Recruiting	EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma	Phase 3	2025-02-03
Active Not Recruiting	LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of M Non-Small Cell Lung Cancer (NSCLC)	Phase 2	2024-10-14
Recruiting	LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC Metastatic Non-small Cell Lung Cancer	Phase 3	2024-07-31
Terminated	EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomit Non-small Cell Lung Cancer	Phase 2	2021-07-12
Completed	Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Best Standard of Care for the Treatment o COVID-19	N/A	2021-02-23
Completed	Open-Label Pilot Study of OPTUNE® With High Density Transducer Arrays for the Treatment of Recurrent GBM Glioblastoma Multiforme	Phase 2	2020-07-14
Completed	Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment Nonsmall Cell Lung Cancer, NSCLC	Phase 3	2016-12-01
Completed	Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-1 Brain Metastases From Non-small Cell Lung Cancer (NSCLC)	Phase 3	2016-07-01
Temporarily Not Available	Continued Access Program for Tumor Treating Fields (TTFields) Used With Chemotherapy (Gemcitabine and Nab-Pacl Locally Advanced Pancreatic Adenocarcinoma	—	—